Allergan Announces 13 Presentations on Chronic Migraine, Upper and Lower Limb Spasticity, Cervical Dystonia and Alzheimer’s Disease at the American Academy of Neurology Meeting in Boston

DUBLIN, April 20, 2017 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that it has 13 presentations at the upcoming 69th American Academy of Neurology (AAN) annual meeting taking place April 22-28, 2017 in Boston. Among the highlights are three podium presentations on Chronic Migraine disease awareness and post-stroke spasticity in adults, and poster presentations in Alzheimer’s Disease. Additionally, two platform presentations showcasing findings from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study were identified as advances in the field of neuroscience and selected for a special session entitled, “Invited Science: Headache.” This session will include six 20-minute lectures highlighting some of the most exciting advances in the headache field.

“Allergan is extremely proud of the breadth of data being presented at AAN as it demonstrates our commitment to high quality research and development in neurology,” said David Nicholson, executive vice president and president of Global R&D Brands at Allergan. “We are also honored that the AAN Science Committee has selected two of our CaMEO studies as part of its special session on headaches. It is a true affirmation of our efforts to advance the science of migraine through ongoing research and clinical investment.”

The scheduled times (noted in local Eastern Time) of the presentations and locations at the Boston Convention and Events Center are as follows:

Chronic Migraine:

• “Epidemiology of Migraine in Men: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study”
  • Program Speaker: Ann Scher, PhD
  • PL8, Invited Science: Headache
  • Mon, 4/24, 3:30-5:30pm
• “Perspectives of Adolescents on the Burden of their Parent’s Migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study”
  • Program Speaker: Richard Lipton, MD, FAAN
  • PL8, Invited Science: Headache
  • Mon, 4/24, 3:30-5:30
• “Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL”
  • Authors: Blumenfeld A, Stark R, Adams A, Orejudos A, Aurora S
  • Poster #178, Session: P2: Headache: Clinical trials and Therapeutics
  • Mon, 4/24, 8:30am-7:00pm
• “Epidemiology of Migraine in Men: Disease Presentation and Comorbidities from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study”
  • Authors: Scher A, Wang S, Katsarava Z, Buse D, Fanning K, Adams A, Lipton R
  • Platform #007, Session: S47: Headache: Basic and Clinical Science
  • Thurs, 4/27, 3:30pm-5:30pm
• “The Effect of Psychiatric Symptoms on Headache-Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study”
  • Authors: Lipton R, Chu M, Seng E, Reed M, Fanning K, Adams A, Buse D
  • Platform #007, Session: S52: Headache: Clinical Trials and Disease Burden
  • Fri, 4/28, 1:00pm-3:00pm

Spasticity:

• “Safety and Efficacy of High-Dose OnabotulinumtoxinA for Post-Stroke Upper Limb Spasticity: Results of a Double-Blind, Placebo-Controlled Trial”
  • Authors: Patel A, Geis C, Alter K, Pan G, Thorpe A, James L, Dimitrova R
  • Poster #027, Session: P3: Movement Disorders: Dystonia and Neurotoxin Therapies
  • Tues, 4/25, 8:30am-7:00pm
• “The Adult Spasticity International Registry (ASPIRE) Study: 1-Year Results”
  • Authors: Francisco G, Bandari D, Bavikatte G, Jost W, Adams A, Largent J, Esquenazi A
  • Poster #034, Session: P4: Neuro-Rehabilitation: Motor Recovery and Spasticity Treatment
  • Wed, 4/26, 8:30am-7:00pm
• “Safety of OnabotulinumtoxinA Treatment With Concomitant Antithrombotic Therapy in Patients With Post-stroke Spasticity: A Pooled Analysis of Randomized, Double-Blind Studies”
  • Authors: Dimitrova R, James L, Liu C, Orejudos A, Yushmanova I, Brin M
  • Platform #008, Session: S56: Movement Disorders: Huntington’s Disease and Drug-induced Dyskinesias
  • Fri, 4/28, 3:30pm-5:30pm

Cervical Dystonia:

• “Clinical Relevance of Treatment With OnabotulinumtoxinA in Patients With Cervical Dystonia: Results From the CD Probe Study”
  • Authors: Mari Z, Dashtipour K, Jankovic J, Adler C, Schwartz M, Brin M
  • Poster #016, Session: P3: Movement Disorders: Dystonia and Neurotoxin Therapies
  • Tues, 4/25, 8:30am-7:00pm

Alzheimer’s Disease:

• “Memantine Added to Background Cholinesterase-Inhibitors Reduces Agitation and Neuropsychiatric Symptoms in Alzheimer’s Disease”
  • Authors:  Atri A, Grossberg G, Hendrix S, Ellison N, Johnstone M, Edwards J
  • Poster #082, Session: P3: Aging and Dementia: Therapeutic Approaches I
  • Tues, 4/25, 8:30am-7:00pm
• “Improved Detection of Treatment Effects in Severe Alzheimer’s Disease: A Quantitatively-derived SIB-based Composite Scale”
  • Authors:  Atri A, Hendrix S, Ellison N, Kane M, Edwards J, Grossberg G
  • Poster #085, Session: P3: Aging and Dementia: Therapeutic Approaches I
  • Tues, 4/25, 8:30am-7:00pm
• “Response Across Multiple Outcome Measures in a Randomized Trial of Extended-release Memantine (28 mg, once daily) in Patients with Moderate to Severe Alzheimer’s Disease Receiving Donepezil”
  • Authors:  Grossberg G, Alva G, Hendrix S, Ellison N, Johnstone M, Edwards J
  • Poster #086, Session: P3: Aging and Dementia: Therapeutic Approaches I
  • Tues, 4/25, 8:30am-7:00pm
• “Efficacy of Memantine ER on Activities of Daily Living: A Post Hoc Responder Analysis From a Randomized Trial in Patients With Moderate-to-severe Alzheimer’s Disease”
  • Authors: Alva G, Grossberg G, Hendrix S, Ellison N, Andersen K, Edwards J
  • Poster #087, Session: P3: Aging and Dementia: Therapeutic Approaches I
  • Tues, 4/25, 8:30am-7:00pm

About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Our Company’s success is powered by our more than 16,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan’s website at www.allergan.com.

Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the year ended December 31, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

 

SOURCE: Allergan plc